Abstract
Currently approved treatments for schizophrenia only minimally affect the cognitive features of the illness that are the most closely related to disability. Hence, there is now considerable effort to repurpose drugs for schizophrenia, and to seek agents that can improve cognition by targeting receptor systems other than the dopaminergic system. The results of these studies have been mixed thus far; however, this continues to be a high-priority area of schizophrenia research and an important unmet need.
| Original language | English |
|---|---|
| Pages (from-to) | 191-193 |
| Number of pages | 3 |
| Journal | Clinical Pharmacology and Therapeutics |
| Volume | 101 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1 Feb 2017 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:Published 2016. This article is a U.S. Government work and is in the public domain in the USA.